ALKS

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 53.5/100

📰 Latest News

Alkermes plc (ALKS) pioneers innovative therapies for central nervous system disorders and cancer, offering a compelling investment in a high-growth biopharmaceutical company with a robust pipeline and established market presence, trading at an attractive 17.01 P/E ratio.

About ALKS

Alkermes plc is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines. They focus on addressing unmet medical needs in central nervous system disorders and oncology.

Alkermes plc Company Overview

Founded in 1987 and headquartered in Dublin, Ireland, Alkermes plc is a biopharmaceutical company committed to developing innovative medicines that address unmet medical needs. The company's focus lies primarily in central nervous system (CNS) disorders and oncology. Alkermes has a portfolio of marketed products, including ARISTADA, an injectable treatment for schizophrenia; VIVITROL, used for alcohol and opioid dependence; and VUMERITY, a treatment for relapsing forms of multiple sclerosis. Additionally, Alkermes collaborates with Janssen to commercialize RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA, all used in the treatment of schizophrenia and schizoaffective disorder. Alkermes is also actively developing LYBALVI, an oral antipsychotic drug candidate, and nemvaleukin alfa, an engineered fusion protein for cancer immunotherapy. With a strong emphasis on research and development, Alkermes seeks to improve patient outcomes and create value for shareholders through its innovative pharmaceutical products and strategic collaborations.

Investment Thesis

Alkermes presents a compelling investment opportunity due to its established portfolio of marketed products, robust pipeline of drug candidates, and strategic collaborations. The company's focus on CNS disorders and oncology, areas with significant unmet medical needs, positions it for sustained growth. With a P/E ratio of 17.01 and a gross margin of 86.0%, Alkermes demonstrates strong profitability and financial health. Growth catalysts include the potential approval and commercialization of LYBALVI and nemvaleukin alfa, which could significantly expand the company's revenue streams. Furthermore, Alkermes' collaborations with Janssen provide a stable revenue base and opportunities for further expansion. The company's commitment to innovation and its established market presence make it an attractive investment for long-term growth.

Key Financial Highlights

• Market Cap of $5.76B reflects substantial investor confidence in Alkermes' pipeline and market position.
• P/E Ratio of 17.01 indicates an attractive valuation relative to earnings, suggesting potential for appreciation.
• Profit Margin of 22.3% demonstrates strong profitability and efficient operations.
• Gross Margin of 86.0% highlights the company's ability to maintain high profitability on its products.
• Beta of 0.46 suggests lower volatility compared to the overall market, making it a potentially stable investment.

Industry Context

Alkermes operates within the biotechnology industry, a sector characterized by high growth potential and significant investment in research and development. The industry is driven by the increasing demand for innovative therapies to address unmet medical needs, particularly in areas such as CNS disorders and oncology. The competitive landscape includes companies like ACADIA Pharmaceuticals (ACAD), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), Arrowhead Pharmaceuticals (ARWR), and CRISPR Therapeutics (CRSP), each focusing on specific therapeutic areas and technologies. Alkermes differentiates itself through its diverse portfolio of marketed products, its robust pipeline, and its strategic collaborations with major pharmaceutical companies.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• LYBALVI Approval and Commercialization: LYBALVI, an oral atypical antipsychotic drug candidate for schizophrenia and bipolar I disorder, represents a significant growth opportunity. The market for antipsychotics is substantial, and LYBALVI's potential approval could capture a significant share. Successful commercialization could generate substantial revenue growth within the next 2-3 years, leveraging Alkermes' existing sales and marketing infrastructure in the CNS space. This is a multi-billion dollar market with ongoing need.
• Nemvaleukin Alfa Development: Nemvaleukin alfa, an engineered fusion protein designed to expand tumor-killing immune cells, holds promise in the oncology space. The market for cancer immunotherapies is rapidly expanding, and positive clinical trial results could lead to regulatory approval and commercialization within the next 3-5 years. This would diversify Alkermes' revenue streams and position it as a player in the high-growth oncology market. The oncology market is estimated to be worth hundreds of billions.
• Expansion of VUMERITY Market Share: VUMERITY, a treatment for relapsing forms of multiple sclerosis, has the potential to gain further market share. The MS market is competitive, but VUMERITY's efficacy and safety profile could drive increased adoption by physicians and patients. Continued marketing efforts and clinical data could support further growth in the coming years, solidifying Alkermes' position in the MS market. The MS therapeutics market is a multi-billion dollar market.
• Strategic Collaborations: Alkermes' existing collaborations with Janssen provide a stable revenue base and opportunities for further expansion. Exploring new partnerships with other pharmaceutical companies could unlock additional value and accelerate the development and commercialization of its pipeline assets. These collaborations could provide access to new markets, technologies, and funding, driving long-term growth. Collaboration is an ongoing process.
• Geographic Expansion: Alkermes currently operates in the United States, Ireland, and internationally. Expanding its geographic footprint into new markets, particularly in Europe and Asia, could drive significant revenue growth. This would require strategic investments in sales and marketing infrastructure, but the potential returns are substantial. This is a long-term opportunity with a timeline of 3-5 years.

Competitive Advantages

• Proprietary drug formulations and patents protect its products from generic competition.
• Established relationships with healthcare providers and payers.
• Specialized expertise in developing and manufacturing complex injectable medications.
• Strong research and development capabilities.

Strengths

• Established portfolio of marketed products.
• Strong research and development capabilities.
• Strategic collaborations with major pharmaceutical companies.
• High gross margin.

Weaknesses

• Reliance on a limited number of key products.
• Competition from larger pharmaceutical companies.
• Regulatory risks associated with drug development.
• High research and development expenses.

Opportunities

• Expansion of existing product lines into new markets.
• Development and commercialization of new drug candidates.
• Strategic acquisitions of complementary businesses.
• Increased adoption of injectable medications.

Threats

• Generic competition for existing products.
• Unfavorable regulatory decisions.
• Clinical trial failures.
• Changes in healthcare reimbursement policies.

What ALKS Does

• Researches and develops pharmaceutical products.
• Commercializes pharmaceutical products.
• Focuses on addressing unmet medical needs.
• Develops treatments for central nervous system (CNS) disorders.
• Develops treatments for oncology.
• Manufactures injectable and oral medications.
• Collaborates with other pharmaceutical companies.

Business Model

• Develops and patents proprietary pharmaceutical products.
• Generates revenue through sales of marketed products like ARISTADA, VIVITROL, and VUMERITY.
• Receives royalties and milestone payments from collaborations with companies like Janssen.
• Invests in research and development to create new drug candidates.

Key Customers

• Patients with schizophrenia.
• Patients with alcohol dependence.
• Patients with opioid dependence.
• Patients with relapsing forms of multiple sclerosis.
• Healthcare providers who prescribe Alkermes' medications.

Competitors

• ACADIA Pharmaceuticals (ACAD): Focuses on CNS disorders, particularly Parkinson's disease psychosis.
• Axsome Therapeutics (AXSM): Develops novel therapies for CNS conditions like depression and migraine.
• Akero Therapeutics (AKRO): Focuses on developing treatments for non-alcoholic steatohepatitis (NASH).
• Arrowhead Pharmaceuticals (ARWR): Develops RNAi-based therapeutics for various diseases.
• CRISPR Therapeutics (CRSP): Pioneers gene-editing therapies for genetic diseases.

Catalysts

• Upcoming: Potential FDA approval and commercial launch of LYBALVI for schizophrenia and bipolar I disorder.
• Ongoing: Continued clinical development and potential approval of nemvaleukin alfa in oncology.
• Ongoing: Expansion of VUMERITY market share in the treatment of relapsing forms of multiple sclerosis.
• Ongoing: Potential for new strategic collaborations with other pharmaceutical companies.
• Ongoing: Positive clinical trial results for pipeline candidates.

Risks

• Potential: Failure to obtain regulatory approval for LYBALVI or nemvaleukin alfa.
• Ongoing: Competition from existing and new therapies in the CNS and oncology markets.
• Ongoing: Dependence on key products and collaborations for revenue.
• Potential: Unfavorable changes in healthcare reimbursement policies.
• Potential: Product liability claims.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Biotechnology

Browse More

Next Steps